目前用于治疗常见变异性免疫缺陷中颗粒状细胞疾病的治疗策略的生物基础
Astrid C van Stigt1,2, Giulia Gualtiero3,4, Francesco Cinetto5
1Laboratory Medical Immunology, Department of Immunology.
Current opinion in allergy and clinical immunology
|October 21, 2024
概括
常见变性免疫缺陷 (CVID) 中的大肠瘤病涉及T和B细胞异常,免疫失调驱动炎症. 目前的治疗方法,如葡萄糖皮质激素和rituximab针对这些途径,为更好的管理提供了希望.
科学领域:
- 免疫学 免疫学 免疫学
- 免疫疾病的发病因子
- 颗粒状疾病 颗粒状疾病
背景情况:
- 常见变性免疫缺陷 (CVID) 中颗粒状细胞疾病的发病原因仍然不太清楚,这使治疗策略复杂化.
- 颗粒状淋巴细胞间歇性肺病 (GLILD) 是CVID患者的一个显著并发症.
研究的目的:
- 审查CVID中颗粒瘤形成的致病性现有知识.
- 探索CVID相关颗粒状体疾病现有和潜在治疗干预措施的生物学基础.
主要方法:
- 关于CVID病原和粒瘤形成的现有文献的综述.
- 分析细粒体病的组织学发现和免疫细胞标记物.
主要成果:
- 在CVID中,颗粒瘤表现为丰富的,无组织的T和B细胞,淋巴细胞增生以及增加的激活标志物 (sIL-2R,IFN-ɣ),表明Th1活性.
- B细胞异常 (升高的IgM,BAFF,CD21低细胞) 与疾病进展相关,与M2巨细胞和中性粒细胞失调相关,表明慢性炎症.
- 目前的治疗方法包括葡萄糖皮质激素,DMARD和生物药物,如Rituximab.
结论:
- 冠状病毒和粒状细胞疾病 (GLILD) 的生物背景与当前的治疗方法有关.
- 了解这些联系有助于开发针对性治疗CVID相关的颗粒状疾病.
相关概念视频
Immunodeficiency Diseases
911
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
911
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Inflammatory Bowel Disease IV: Pharmacological Management
117
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
117
Cystic Fibrosis: Management
143
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
143
Cytotoxic T Cells-mediated Immune Response
853
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
853
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117


